Table 1.
Breast cancer cell lines used in this investigation, together with their molecular subtype, p53 mutational status, response to APR-246 measured at IC50 value, and the fold-change of SLC7A11, TRIM16, SRXN1, and TXNRD1 following treatment with 50 μM APR-246 for 12 Hours*
| Cell Line | Molecular Subtype | p53 Mutational Status⁎ | APR-246 IC50 (μM) |
SLC7A11 |
TRIM16 |
SRXN1 |
TXNRD1 |
||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| FC | P Value | FC | P Value | FC | P Value | FC | P Value | ||||
| BT549 | TN | p.Arg249Ser | 3.1 ± 0.4 | 21.42 ± 3.6 | .0307 | 2.39 ± 0.2 | .0272 | 4.6 ± 0.8 | .0488 | 1.83 ± 0.1 | .0075 |
| MDA-MB-468 | TN | p.Arg280Lys | 1.9 ± 0.3 | 5.0 ± 0.7 | .0093 | 2.79 ± 0.7 | .05 | 1.72 ± 0.1 | .0267 | 1.72 ± 0.3 | .0442 |
| MDA-MB-231 | TN | p.Arg273His | 4.1 ± 1.6 | 5.47 ± 0.9 | .0057 | 9.6 ± 2.8 | .0409 | 1.28 ± 0.1 | .1452 | 2.26 ± 0.4 | .1067 |
| HCC1143 | TN | p.Arg248Gln | 6.8 ± 1.1 | 6.06 ± 0.9 | .0027 | 3.38 ± 0.4 | .01 | 2.5 ± 0.3 | .02 | 3.33 ± 0.64 | .0357 |
| MDA-MB-453 | Her2+ | p.His368delinsGln | 0.9 ± 0.2 | 11.53 ± 1.9 | .003 | 7.8 ± 1.16 | .0042 | 3.71 ± 0.4 | .006 | 3.36 ± 0.5 | .0135 |
| SKBR3 | Her2+ | p.Arg175His | 5.1 ± 0.6 | 2.73 ± 0.5 | .0237 | 1.51 ± 0.2 | .086 | 2.17 ± 0.9 | .272 | 2.96 ± 0.9 | .119 |
| UACC812 | Her2+ | Wild type | 11.3 ± 1.8 | 2.4 ± 0.6 | .0927 | 1.29 ± 0.1 | .0747 | 0.77 ± 0.1 | .1328 | 0.77 ± 0.3 | .4989 |
| MCF7 | ER+ | Wild type | 31.1 ± 24.6 | 2.17 ± 0.3 | .0223 | 1.65 ± 0.15 | .0248 | 1.45 ± 0.1 | .0115 | 1.74 ± 0.2 | .0654 |
| MCF10A | Epithelial | Wild type | 5.2 ± 1.3 | 2.16 ± 0.5 | .0923 | 0.88 ± 0.17 | .5203 | 0.99 ± 0.2 | .0717 | 0.59 ± 0.11 | .0674 |
Gene expression was based on qPCR. P values were calculated using paired t test. Cell lines shown in bold were also analyzed by RNA-seq. FC = fold change.
*
Source; UMD TP53 Mutation database.